KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Investment Income: 2018-2024

Historic Non Operating Investment Income for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to -$6.0 million.

  • Royalty Pharma's Non Operating Investment Income rose 33.33% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 1226.76%. This contributed to the annual value of -$6.0 million for FY2024, which is 162.01% down from last year.
  • Royalty Pharma's Non Operating Investment Income amounted to -$6.0 million in FY2024, which was down 162.01% from -$2.3 million recorded in FY2023.
  • Royalty Pharma's 5-year Non Operating Investment Income high stood at $96.6 million for FY2022, and its period low was -$42.1 million during FY2020.
  • Its 3-year average for Non Operating Investment Income is $29.4 million, with a median of -$2.3 million in 2023.
  • As far as peak fluctuations go, Royalty Pharma's Non Operating Investment Income spiked by 548.68% in 2022, and later crashed by 162.01% in 2024.
  • Yearly analysis of 5 years shows Royalty Pharma's Non Operating Investment Income stood at -$42.1 million in 2020, then skyrocketed by 48.83% to -$21.5 million in 2021, then soared by 548.68% to $96.6 million in 2022, then slumped by 102.37% to -$2.3 million in 2023, then slumped by 162.01% to -$6.0 million in 2024.